D3receptor test in vitro predicts decreased cocaine self- administration in rats

NeuroReport

Volumn 8, Issue 9-10, 1997, Pages 2373-2377

  Caine, S Barak ^a,b   Koob, George F ^a   Parsons, Loren H ^a   Everitt, Barry J ^c   Schwartz, Jean Charles ^d   Sokoloff, Pierre ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d CENTRE PAUL BROCA   (France)

Author keywords

Cocaine; Dopamine receptor; Drug abuse; Mitogenesis; Nafadotride; PD 128,907; Pramipexole; Quinelorane; Rat; Self administration

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; APOMORPHINE; BROMOCRIPTINE; DOPAMINE; DOPAMINE 2 RECEPTOR; LISURIDE; PRAMIPREXOLE; QUINALORANE; QUINPIROLE; UNCLASSIFIED DRUG; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H (1)BENZOPYRANO(4,3 B) 1,4 OXAZIN 9 OL; 3,4,4A,10B-TETRAHYDRO-4-PROPYL-2H,5H-(1)BENZOPYRANO(4,3-B)-1,4-OXAZIN-9-OL; BENZOPYRAN DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; COCAINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRD3 PROTEIN, RAT; NAFADOTRIDE; NAPHTHALENE DERIVATIVE; OXAZINE DERIVATIVE; PRAMIPEXOL; PYRROLIDINE DERIVATIVE; QUINELORANE; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; DOPAMINERGIC SYSTEM; DRUG ABUSE; MITOGENESIS; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; DRUG SELF ADMINISTRATION; IN VITRO STUDY; MALE; OPIATE ADDICTION; RAT;

ANIMALS; BENZOPYRANS; BENZOTHIAZOLES; COCAINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MALE; NAPHTHALENES; OPIOID-RELATED DISORDERS; OXAZINES; PYRROLIDINES; QUINOLINES; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SELF ADMINISTRATION; THIAZOLES;

EID: 0030612564     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199707070-00054     Document Type: Article

References (25)

1. Mendelson JM and Mello NK. New Eng J Med 334, 965-972 (1996).
2. Gawin F. Science 251, 1580-1584 (1991).
3. Withiers NW, Pulvirenti L, Koob GF et al. J Clin Psychopharmacol 15, 63-78 (1995).
4. Bergman J, Kamien JB and Spealman R. Behav Pharmacol 1, 355-363 (1990) .
5. Sokoloff P, Giros B, Martres M-P et al. Nature 347, 146-151 (1990).
6. Caine SB and Koob GF. Science 260, 1814-1816 (1993).
7. Caine SB and Koob GF. Behav Pharmacol 6, 333-347 (1995).
8. Sautel F, Griffon N, Levesque D et al. NeuroReport 6, 329-332 (1995).
9. Sautel F, Griffon N, Sokoloff P et al. J Pharmacol Exp Ther 275, 1239-1246 (1995).
10. Pulvirenti L and Koob GF. Pharmacol Biochem Behav 47, 819-822 (1994).
11. Hubner C and Koob GF. Psychopharmacology 3, 101-108 (1990).
12. Levesque D, Diaz J, Pilon C et al. Proc Natl Acad Sci USA 89, 8155-8159 (1992).
13. Chio CL, Lajiness ME and Huff RM. Mol Pharmacol 45, 51-60 (1994).
14. Freedman SB, Patel S, Marwood R et al. J Pharmacol Exp Ther 268, 417-426 (1994).
15. Millan MJ, Peglion J-L, Vian J et al. J Pharmacol Exp Ther 275, 885-898 (1995).
16. Pugsley TA, Davis MD, Akune HC et al. J Pharmacol Exp Ther 275, 1355-1366 (1995).
17. Malmberg A and Mohell N. Pharmacol Exp Ther 274, 790-797 (1995).
18. Burris KD, Pacheco MA, Filtz TM et al. Neuropsychopharmacology 12, 335-345 (1995).
19. Lamas X, Negus SS, Nader MA and Mello NK. Psychopharmacology 124, 306-314 (1996).
20. Spealman R. J Pharmacol Exp Ther 278, 1128-1137 (1996).
21. Sanger DJ, Depoortere R and Perrault G. Behav Pharmacol 7, 477-482 (1996).
22. Parsons LH, Caine SB, Sokoloff P et al. J. Neurochem 67, 1078-1089 (1996).
23. Murray AM, Ryoo H, Gurevich E et al. Proc Natl Acad Sci USA 91, 11271-11275 (1994).
24. Staley JK and Mash DC. J Neurosci 16, 6100-6106 (1996).
25. Nader MA and Mach RH. Psychopharmacology 125, 13-22 (1996).